STOCK TITAN

Edgewise Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Edgewise Therapeutics (NASDAQ: EWTX) announced participation in the virtual Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021, at 5:30 p.m. ET. Members of the management team will engage in a fireside chat and one-on-one investor meetings. The webcast will be available live through the investor relations section of Edgewise’s website and can be accessed for 90 days post-event. Edgewise focuses on developing innovative therapies for rare muscle disorders, leveraging its expertise in muscle biology and small molecule engineering.

Positive
  • None.
Negative
  • None.

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, today announced that members of its management team will participate in a fireside chat and one-on-one investor meetings at the virtual Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 5:30 p.m. ET.

The fireside chat will be webcast live on the Events and Presentations page under the investor relations section of Edgewise Therapeutic’s website at https://investors.edgewisetx.com/events-and-presentations and accessible for 90 days following the presentation. It is recommended that users connect to the webcast several minutes prior to the start to ensure a timely connection.

About Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle focused drug discovery platform. Edgewise’s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn.

FAQ

What event is Edgewise Therapeutics participating in on June 9, 2021?

Edgewise Therapeutics will participate in the virtual Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021.

What time is the Edgewise Therapeutics presentation at the Goldman Sachs Conference?

The presentation will take place at 5:30 p.m. ET.

How can I watch the Edgewise Therapeutics fireside chat?

The fireside chat can be watched live on the Events and Presentations page of Edgewise’s investor relations website.

How long will the Edgewise Therapeutics webcast be available after the event?

The webcast will be accessible for 90 days following the presentation.

What is the focus of Edgewise Therapeutics?

Edgewise Therapeutics focuses on developing treatments for severe, rare muscle disorders.

Edgewise Therapeutics, Inc.

NASDAQ:EWTX

EWTX Rankings

EWTX Latest News

EWTX Stock Data

3.18B
93.77M
0.47%
112.31%
9.05%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BOULDER